World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
40
Citations
8997
World Ranking
5486
National Ranking
2069

Larisa V. Gubareva publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Larisa V. Gubareva sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 71 publications — 1st percentile

1% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Larisa V. Gubareva D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Larisa V. Gubareva sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 40 D-Index — 1st percentile

1% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Larisa V. Gubareva is affiliated with the Centers for Disease Control and Prevention in the United States. Their research focuses primarily on medical and molecular biological aspects of infectious diseases, with several contributions to the field of epidemiology.

Their research includes work in the following fields of study:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these areas, their subfields of study include:

  • Epidemiology
  • Molecular Biology
  • Modeling and Simulation

Key topics addressed in their work comprise:

  • Influenza Virus Research Studies
  • Protein Structure and Dynamics
  • COVID-19 epidemiological studies
  • Respiratory viral infections research
  • Metabolomics and Mass Spectrometry Studies

Among their recent papers are the following:

  • Multicountry Spread of Influenza A(H1N1)pdm09 Viruses with Reduced Oseltamivir Inhibition, 2024, Emerging Infectious Diseases
  • Antiviral Susceptibility Monitoring: Testing Algorithm, Methods, and Findings for Influenza Season, 2023-2024, 2025, SSRN Electronic Journal

Frequent collaborators in research include:

  • Mira C. Patel
  • Ha Nguyen
  • Philippe Noriel Q. Pascua
  • John Steel
  • Rebecca Kondor

Publications by Larisa V. Gubareva appear in venues including:

  • Emerging Infectious Diseases
  • SSRN Electronic Journal

Best Publications

  • Emergence of a novel swine-origin influenza A (H1N1) virus in humans.

    Seema Jain;Lyn Finelli;Michael W. Shaw;Stephen Lindstrom

  • Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans

    Rebecca J. Garten;C. Todd Davis;Colin A. Russell;Colin A. Russell;Bo Shu

  • Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).

    Anthony E Fiore;Alicia Fry;David Shay;Larisa Gubareva

  • Influenza virus neuraminidase inhibitors

    Larisa V Gubareva;Laurent Kaiser;Frederick G Hayden

  • Triple-Reassortant Swine Influenza A (H1) in Humans in the United States, 2005–2009

    Vivek Shinde;Carolyn B Bridges;Timothy M Uyeki;Bo Shu

  • Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States

    Nila J. Dharan;Larisa V. Gubareva;John J. Meyer;Margaret Okomo-Adhiambo

  • Surveillance of Resistance to Adamantanes among Influenza A(H3N2) and A(H1N1) Viruses Isolated Worldwide

    Varough M. Deyde;Xiyan Xu;Rick A. Bright;Michael Shaw

  • Changes in influenza and other respiratory virus activity during the COVID-19 pandemic-United States, 2020-2021.

    Sonja J Olsen;Amber K Winn;Alicia P Budd;Mila M Prill

  • Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008

    Tiffany G. Sheu;Varough M. Deyde;Margaret Okomo-Adhiambo;Rebecca J. Garten

  • Evidence for Zanamivir Resistance in an Immunocompromised Child Infected with Influenza B Virus

    Larisa V. Gubareva;Mikhail N. Matrosovich;Malcolm K. Brenner;Richard C. Bethell

  • Inhaled zanamivir for the prevention of influenza in families

    Frederick G. Hayden;Larisa V. Gubareva;Arnold S. Monto;Thomas C. Klein

  • Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses.

    Laurent Kaiser;R. Scott Fritz;Stephen E. Straus;Larisa Gubareva

  • Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.

    Larisa V. Gubareva;Laurent Kaiser;Mikhail N. Matrosovich;Mikhail N. Matrosovich;Yee Soo-Hoo

  • Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.

    L V Gubareva;M J Robinson;R C Bethell;R G Webster

  • Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.

    Michael G. Ison;Larisa V. Gubareva;Robert L. Atmar;John Treanor

  • Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.

    Vasiliy P. Mishin;Frederick G. Hayden;Larisa V. Gubareva

  • Influenza Activity — United States, 2015–16 Season and Composition of the 2016–17 Influenza Vaccine

    Stacy L Davlin;Lenee Blanton;Krista Kniss;Desiree Mustaquim

  • Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection

    Michael P. Malakhov;Laura M. Aschenbrenner;Donald F. Smee;Miles K. Wandersee

  • Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants

    Larisa V. Gubareva;Robert G. Webster;Robert G. Webster;Frederick G. Hayden

  • Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.

    Unknown

  • Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.

    L. Gubareva;M. Okomo-Adhiambo;V. Deyde;A. M. Fry

  • Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.

    Aeron C Hurt;Tawee Chotpitayasunondh;Nancy J Cox;Rod Daniels

  • Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.

    L V Gubareva;R Bethell;G J Hart;K G Murti

  • Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

    Ha T Nguyen;Alicia M Fry;Larisa V Gubareva

  • Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient.

    David M Weinstock;Larisa V Gubareva;Gianna Zuccotti

  • Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015

    Adam Meijer;Helena Rebelo-de-Andrade;Helena Rebelo-de-Andrade;Vanessa Correia;Vanessa Correia;Terry Besselaar

  • Characterization of Influenza A/HongKong/156/97 (H5N1) Virus in a Mouse Model and Protective Effect of Zanamivir on H5N1 Infection in Mice

    Larisa V. Gubareva;Jonathan A. McCullers;Richard C. Bethell;Robert G. Webster

  • Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.

    Larisa V. Gubareva;Robert G. Webster;Robert G. Webster;Frederick G. Hayden

  • Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial

    Alicia M Fry;Doli Goswami;Kamrun Nahar;Amina Tahia Sharmin

  • Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.

    Luis Barroso;John Treanor;Larisa Gubareva;Frederick G Hayden

  • Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014

    Unknown

  • Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.

    Donald F. Smee;Kevin W. Bailey;Min-Hui Wong;Barry R. O’Keefe

  • Recovery of a Multidrug-Resistant Strain of Pandemic Influenza A 2009 (H1N1) Virus Carrying a Dual H275Y/I223R Mutation from a Child after Prolonged Treatment with Oseltamivir

    Ha T. Nguyen;Alicia M. Fry;P. Ann Loveless;Alexander I. Klimov

  • In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication

    Warren M. Kati;Debra Montgomery;Robert Carrick;Larisa Gubareva

Frequent Co-Authors

Alicia M. Fry
Alicia M. Fry Emory University
Alexander Klimov
Alexander Klimov Centers for Disease Control and Prevention
Rebecca Garten
Rebecca Garten National Center for Immunization and Respiratory Diseases
John Barnes
John Barnes Centers for Disease Control and Prevention
Xiyan Xu
Xiyan Xu Centers for Disease Control and Prevention
Joseph S. Bresee
Joseph S. Bresee Centers for Disease Control and Prevention
David E. Wentworth
David E. Wentworth Centers for Disease Control and Prevention
Lynnette Brammer
Lynnette Brammer Centers for Disease Control and Prevention
Jacqueline M. Katz
Jacqueline M. Katz Emory University
Stephen Lindstrom
Stephen Lindstrom Centers for Disease Control and Prevention

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students studying Microbiology in the USA, expanding career options through related online degrees can be a smart move. Fields such as health information management and medical coding offer promising opportunities that align well with a microbiology background.

One career to consider is becoming a certified professional coder, which requires specialized training in medical coding systems. Exploring how to become a certified professional coder can open doors to healthcare administration roles with competitive salaries.

For those interested in broader healthcare data management, pursuing a bachelor of science in health information management salary offers insight into this field’s lucrative potential and growing demand.

To ensure quality education that meets industry standards, consider enrolling in cahiim accredited health information management programs online. These programs provide recognized credentials to advance your career.

Additionally, for those seeking quicker entry into the field, the fastest online medical billing and coding certificate programs offer accelerated pathways to certification, making it easier to start work promptly while leveraging microbiology knowledge in healthcare settings.

Best Scientists Citing Larisa V. Gubareva

Trending Scientists

Recently Published Articles